Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study
- PDF / 611,643 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 32 Downloads / 173 Views
LETTER
Hydroxychloroquine pharmacokinetic in COVID‑19 critically ill patients: an observational cohort study Benoit Painvin1* , Pauline Guillot1, Marie‑Clémence Verdier2,3, Arnaud Gacouin1,3 and Adel Maamar1,3 © 2020 Springer-Verlag GmbH Germany, part of Springer Nature
Dear Editor, The benefit of hydroxychloroquine (HCQ) in the treatment of coronavirus disease (COVID-19) is still under investigation, and randomized control trials worldwide are currently recruiting patients. Data on HCQ pharmacokinetics (PK) exist in lupus patients but are scarce in COVID-19 critically ill patients [1–3]. In our intensive care unit (ICU), patients were started on a 10-day oral course of HCQ 200 mg t.i.d, or 200 mg b.i.d if they had acute kidney injury (AKI) defined as creatinine clearance
Data Loading...
